Marinus Pharma

Radnor, United States Founded: 2003 • Age: 23 yrs Acquired By Immedica
Developer of therapeutics to treat seizure disorders
Request Access

About Marinus Pharma

Marinus Pharma is a company based in Radnor (United States) founded in 2003 was acquired by Immedica in December 2024.. Marinus Pharma has raised $71.58 million across 5 funding rounds from investors including Canaan, Immedica and Southern New Hampshire Health. Marinus Pharma offers products and services including Ganaxolone. Marinus Pharma operates in a competitive market with competitors including Arvelle Therapeutics, ORPHELIA Pharma, Corlieve Therapeutics, EpilepsyGTx and GenEp, among others.

  • Headquarter Radnor, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Marinus Pharmaceuticals, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $71.58 M (USD)

    in 5 rounds

  • Latest Funding Round
    $1.23 M (USD), Post-IPO

    Apr 04, 2022

  • Investors
    Canaan

    & 6 more

  • Employee Count
    Employee Count
  • Acquired by
    Immedica

    (Dec 30, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Marinus Pharma

Marinus Pharma offers a comprehensive portfolio of products and services, including Ganaxolone. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Medication for treating severe epilepsy and seizure disorders.

People of Marinus Pharma
Headcount 50-200
Employee Profiles 24
Board Members and Advisors 15
Employee Profiles
People
Thomas J. Lyons
SVP, Corporate & Business Development & Commercial Planning
People
Dayong Li
SVP, Biometrics
People
Maria Bosak
Senior Executive Assistant
People
Dave Chappell
Regiona Account Manager - Atlantic Coast

Unlock access to complete

Board Members and Advisors
people
Nicola Specchio
Scientific Advisory Board Member
people
Elizabeth Thiele
Scientific Advisory Board Member
people
Aatif M. Husain
Scientific Advisory Board Member
people
Sara Nochur
Director

Unlock access to complete

Funding Insights of Marinus Pharma

Marinus Pharma has successfully raised a total of $71.58M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.23 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $1.2M
  • First Round

    (25 Oct 2005)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2022 Amount Post-IPO - Marinus Pharma Valuation

investors

Dec, 2019 Amount Post-IPO - Marinus Pharma Valuation

investors

Jul, 2013 Amount Series C - Marinus Pharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Marinus Pharma

Marinus Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaan, Immedica and Southern New Hampshire Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Canaan is recognized as an early-stage venture capital firm.
Founded Year Domain Location
Biotech funding, drug development support, and investment in life sciences.
Founded Year Domain Location
Healthcare investments are managed by corporate-backed venture capital fund RusnanoMedInvest.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Marinus Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Marinus Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Marinus Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Marinus Pharma

Marinus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arvelle Therapeutics, ORPHELIA Pharma, Corlieve Therapeutics, EpilepsyGTx and GenEp, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Small molecule therapies are developed for partial-onset seizures treatment.
domain founded_year HQ Location
Therapies for pediatric neurology, oncology, and hematology are developed.
domain founded_year HQ Location
Therapeutics for neurological disorders are developed using AAV gene delivery.
domain founded_year HQ Location
Gene therapies for focal refractory epilepsy are developed.
domain founded_year HQ Location
Therapeutics for epilepsy are developed targeting ion channel mutations.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Marinus Pharma

Frequently Asked Questions about Marinus Pharma

When was Marinus Pharma founded?

Marinus Pharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Marinus Pharma located?

Marinus Pharma is headquartered in Radnor, United States. It is registered at Radnor, Pennsylvania, United States.

Is Marinus Pharma a funded company?

Marinus Pharma is a funded company, having raised a total of $71.58M across 5 funding rounds to date. The company's 1st funding round was a Series C of $21.77M, raised on Oct 25, 2005.

What does Marinus Pharma do?

Founded in 2003, Marinus Pharma is based in Radnor, United States, where pharmaceuticals targeting seizure disorders are developed. The lead product, Ganaxolone, is provided in intravenous and oral forms for addressing status epilepticus and rare orphan epilepsies. Operations encompass drug development within the neurology sector, alongside advocacy and associated initiatives.

Who are the top competitors of Marinus Pharma?

Marinus Pharma's top competitors include Arvelle Therapeutics, ORPHELIA Pharma and Corlieve Therapeutics.

What products or services does Marinus Pharma offer?

Marinus Pharma offers Ganaxolone.

Who are Marinus Pharma's investors?

Marinus Pharma has 7 investors. Key investors include Canaan, Immedica, Southern New Hampshire Health, Sofinnova, and RusnanoMedInvest.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available